COMP <GO>
VMD vs UNH // EV/EBITDA & P/E VALUATION
Viemed Healthcare Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: VMD 7
— UNH 6
▲ EV/EBITDA & P/E VALUATION LEADER: VMD
LAST: $9.95 (-0.40%) • MKT CAP: $379.0M
valuation
6.6x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
valuation
16.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VMD VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VMD | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.50% | 88.57% | -31.07 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.00% | 11.47% | +1.53 | VMD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.6x | 16.4x | -9.85 | VMD | /valuation <GO> |
| Free Cash Flow Yield | 3.15% | 6.48% | -3.33 | UNH | /fcf-yield <GO> |
| Operating Margin | 8.50% | 4.82% | +3.68 | VMD | /operating-margins <GO> |
| Net Profit Margin | 5.70% | 3.14% | +2.56 | VMD | /net-margins <GO> |
| Revenue Growth (YoY) | 20.50% | 6.46% | +14.04 | VMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.59 | 3.12 | +3.47 | VMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | VMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 59.2 | -6.09 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.7x | 17.1x | +3.61 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $379.0M | $368.83B | -$368.45B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VMD REV | UNH REV | VMD GROSS % | UNH GROSS % | VMD FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $270.3M | $447.57B | 57.5% | 88.7% | $11.9M | $16.07B |
| FY 2024 | $224.3M | $400.28B | 59.4% | 88.3% | $1.3M | $20.70B |
| FY 2023 | $183.0M | $371.62B | — | 89.6% | $45.2M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VMD // BETA —
UNH // BETA 0.33